The following randomized, double-masked pivotal trials were conducted for the 5 LUCENTIS indications: wAMD: MARINA—Phase III, multicenter, 2-year, sham injection–controlled study; primary end point at 1 year. ANCHOR—Phase III, multicenter, 2-year, active treatment–controlled study; primary end point at 1 year. PIER—Phase IIIb, 2-year, sham injection–controlled study; primary end point at 1 year. HARBOR—Phase III, multicenter, 2-year, active treatment–controlled dose-response study; primary end point at 1 year. RVO: BRAVO—Phase III, multicenter, 1-year, sham injection–controlled study; primary end point at 6 months. CRUISE—Phase III, multicenter, 1-year, sham injection–controlled study; primary end point at 6 months. DME and DR in Patients with DME: RISE—Phase III, multicenter, 3-year, sham injection–controlled study; primary end point at 2 years. RIDE—Phase III, long-term, 3-year, sham injection–controlled study; primary end point at 2 years. mCNV: RADIANCE—Phase III, multicenter, 1-year, active–controlled study; key clinical outcomes at month 3.1-9

VEGF, vascular endothelial growth factor.

(see references 1-7, 9)

Resources
Resources for your patients.
LUCENTIS Direct
Simple, personalized ordering.
LUCENTIS Co-pay Card Program
Support for your patients with commercial insurance.
LUCENTIS Access Solutions
Access and reimbursement services for your patients.